Kalaris Therapeutics, Inc.
KLRS- 1M
- -35.5%
Kalaris Therapeutics, Inc. in brief
Kalaris Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. Its market value was $45 M on 26 October 2026, which makes it the 21,699th largest listed company in the world and the 3,909th largest in the USA on this site. It employs about 107 people. Its shares trade under the symbol KLRS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Kalaris Therapeutics, Inc.
AlloVir is a Late Clinical Stage Cell Therapy company. The company annual revenue is 49.9 million USD and 21 employees as on 2020. The headquarters is in USA.
Kalaris Therapeutics, Inc. timeline
- 2018
- ✎Renamed Allovir, Inc.Formerly ViraCyte, Inc..
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as Allovir, Inc.Final prospectus filed with the SEC on 30 July 2020; shares registered for exchange trading on 27 July 2020.
- 2025
- ✎Renamed Kalaris Therapeutics, Inc.Formerly Allovir, Inc..
Events of Kalaris Therapeutics, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,541 (Jan 2021) · #2,821 (Jan 2022) · #3,155 (Dec 2022) · #3,066 (Jul 2023) · #3,863 (Jan 2024) · #3,695 (Sep 2026) · #3,913 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -86.6%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -55.1%
- Liabilities / assets
- 35.3%
- R&D / revenue
- 10156.3%
- Profit per employee
- $-406 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-46M | $-43M | — |
| Dec 2024 | — | — | $-52M | $-69M | — |
| Dec 2023 | — | — | $-200M | $-190M | — |
| Dec 2022 | — | — | $-171M | $-169M | — |
| Dec 2021 | — | — | $-170M | $-172M | — |
| Dec 2020 | — | — | $-71M | $-70M | — |
| Dec 2019 | $0M | — | $-27M | $-24M | -14900.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-38M | $0M | $-39M | $-2.85 | — |
| Dec 2024 | $-21M | — | — | $-51.77 | — |
| Dec 2023 | $-124M | — | — | $-42.09 | — |
| Dec 2022 | $-142M | — | — | $-2.20 | — |
| Dec 2021 | $-106M | $0M | $-106M | $-2.74 | — |
| Dec 2020 | $-61M | $0M | $-61M | $-2.59 | — |
| Dec 2019 | $-20M | $0M | $-21M | $-18.54 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 20, 20268-KCurrent reportDirectors or officers changed
- Jul 17, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jul 6, 20268-KCurrent reportDirectors or officers changed
- Jun 4, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 24, 2026DEF 14AProxy statement
- Apr 10, 20268-KCurrent reportDirectors or officers changed
Official filings of Kalaris Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-46 M
- Net income
- $-43 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $122 M
- Total liabilities
- $43 M
- Total equity
- $79 M
As of December-2025
Top 54 institutional investors in Kalaris Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Samsara Biocapital, LLC | 12,881,175 | 0 (0.00%) | 54.11% | $37 M | Nov 16, 2026 |
| 2 | RTW Investments, LP | 1,300,000 | 0 (0.00%) | 5.46% | $4 M | Nov 16, 2026 |
| 3 | Alyeska Investment Group, L.P. | 472,687 | -100,000 (-17.46%) | 1.99% | $1 M | Nov 16, 2026 |
| 4 | Siren, L.L.C. | 356,559 | -79,239 (-18.18%) | 1.50% | $1 M | Nov 12, 2026 |
| 5 | Vanguard Capital Management LLC | 330,928 | -67,784 (-17.00%) | 1.39% | $1 M | Nov 13, 2026 |
| 6 | Ikarian Capital, LLC | 248,257 | -111,743 (-31.04%) | 1.04% | $1 M | Nov 16, 2026 |
| 7 | Renaissance Technologies LLC | 176,863 | +27,512 (+18.42%) | 0.74% | $1 M | Nov 12, 2026 |
| 8 | Verdad Advisers, LP | 140,232 | +59,935 (+74.64%) | 0.59% | $0 M | Nov 16, 2026 |
| 9 | UBS Group AG | 110,187 | -151,944 (-57.96%) | 0.46% | $0 M | Nov 10, 2026 |
| 10 | Raymond James Financial Inc | 101,496 | +4,332 (+4.46%) | 0.43% | $0 M | Nov 12, 2026 |
| 11 | WHI TRUST Co LLC | 97,493 | 0 (0.00%) | 0.41% | $0 M | Nov 12, 2026 |
| 12 | Woodline Partners LP | 90,000 | -10,000 (-10.00%) | 0.38% | $0 M | Nov 16, 2026 |
| 13 | Geode Capital Management, LLC | 78,859 | -35,178 (-30.85%) | 0.33% | $0 M | Nov 6, 2026 |
| 14 | Boothbay Fund Management, LLC | 63,623 | -28,638 (-31.04%) | 0.27% | $0 M | Nov 16, 2026 |
| 15 | ADAR1 Capital Management, LLC | 60,000 | -40,000 (-40.00%) | 0.25% | $0 M | Nov 16, 2026 |
| 16 | BlackRock, Inc. | 58,619 | +4,177 (+7.67%) | 0.25% | $0 M | Nov 13, 2026 |
| 17 | State Street Corp | 51,210 | +24,700 (+93.17%) | 0.22% | $0 M | Nov 12, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 47,553 | -18,626 (-28.14%) | 0.20% | $0 M | Nov 13, 2026 |
| 19 | Belpointe Asset Management LLC | 40,000 | 0 (0.00%) | 0.17% | $0 M | Nov 9, 2026 |
| 20 | Fortis Capital Advisors, LLC | 40,000 | 0 (0.00%) | 0.17% | $0 M | Nov 9, 2026 |
| 21 | Goldman Sachs Group Inc | 39,616 | +23,562 (+146.77%) | 0.17% | $0 M | Nov 16, 2026 |
| 22 | Citadel Advisors LLC | 39,219 | -56,553 (-59.05%) | 0.16% | $0 M | Nov 16, 2026 |
| 23 | Connor, Clark & Lunn Investment Management Ltd. | 35,678 | +5,671 (+18.90%) | 0.15% | $0 M | Nov 10, 2026 |
| 24 | Stonepine Capital Management, LLC | 33,842 | +3,720 (+12.35%) | 0.14% | $0 M | Nov 13, 2026 |
| 25 | Morgan Stanley | 26,773 | -45,553 (-62.98%) | 0.11% | $0 M | Nov 13, 2026 |
Show all 54: investors 26 to 54
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Northern Trust Corp | 25,833 | -6 (-0.02%) | 0.11% | $0 M | Nov 16, 2026 |
| 27 | HRT Financial LP | 25,560 | +11,837 (+86.26%) | 0.11% | $0 M | Nov 13, 2026 |
| 28 | Velan Capital Investment Management LP | 25,000 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 29 | WealthTrust Asset Management, LLC | 23,604 | +3,188 (+15.62%) | 0.10% | $0 M | Oct 22, 2026 |
| 30 | Quadrature Capital Ltd | 23,287 | +6,760 (+40.90%) | 0.10% | $0 M | Nov 13, 2026 |
| 31 | Bridgeway Capital Management, LLC | 22,500 | -10,000 (-30.77%) | 0.09% | $0 M | Nov 16, 2026 |
| 32 | Empowered Funds, LLC | 22,500 | New | 0.09% | $0 M | Nov 13, 2026 |
| 33 | Jane Street Group, LLC | 19,594 | New | 0.08% | $0 M | Nov 12, 2026 |
| 34 | Squarepoint Ops LLC | 18,947 | -19,828 (-51.14%) | 0.08% | $0 M | Nov 9, 2026 |
| 35 | RBF Capital, LLC | 17,391 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 36 | Dimensional Fund Advisors LP | 15,958 | 0 (0.00%) | 0.07% | $0 M | Nov 4, 2026 |
| 37 | XTX Topco Ltd | 14,726 | New | 0.06% | $0 M | Nov 16, 2026 |
| 38 | Nano Cap New Millennium Growth Fund L P | 14,000 | +1,500 (+12.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 39 | Independent Advisor Alliance | 12,625 | -5,500 (-30.34%) | 0.05% | $0 M | Nov 10, 2026 |
| 40 | FMR LLC | 7,806 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 41 | Federation des caisses Desjardins du Quebec | 6,000 | New | 0.03% | $0 M | Nov 16, 2026 |
| 42 | Nuveen, LLC | 4,639 | New | 0.02% | $0 M | Nov 10, 2026 |
| 43 | Caitong International Asset Management Co., Ltd | 1,559 | +1,552 (+22171.43%) | 0.01% | $0 M | Oct 29, 2026 |
| 44 | Tower Research Capital LLC (TRC) | 838 | -1,722 (-67.27%) | 0.00% | $0 M | Nov 16, 2026 |
| 45 | Vanguard Global Advisers, LLC | 725 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 46 | Strengthening Families & Communities, LLC | 268 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
| 47 | Jpmorgan Chase & Co | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 48 | BNP Paribas Financial Markets | 46 | -6 (-11.54%) | 0.00% | $0 M | Nov 12, 2026 |
| 49 | Steward Partners Investment Advisory, LLC | 21 | -2,194 (-99.05%) | 0.00% | $0 M | Nov 13, 2026 |
| 50 | Barclays PLC | 17 | -286 (-94.39%) | 0.00% | $0 M | Nov 6, 2026 |
| 51 | Royal Bank Of Canada | 14 | +2 (+16.67%) | 0.00% | $0 M | Nov 16, 2026 |
| 52 | Harbour Investments, Inc. | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 53 | SBI Securities Co., Ltd. | 5 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 54 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Kalaris Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 255,337 | $1 M | 1.1% | <0.01% | +44% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 137,373 | $1 M | 0.58% | <0.01% | +89% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 34,574 | $0 M | 0.15% | <0.01% | +1.8% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 32,500 | $0 M | 0.14% | 0.09% | +44% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 25,924 | $0 M | 0.11% | <0.01% | +198% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 16,829 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 9,885 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 9,575 | $0 M | 0.04% | <0.01% | +8.1% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 8,020 | $0 M | 0.03% | <0.01% | −4.9% | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 7,806 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,002 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 3,296 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 2,750 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 2,614 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,725 | $0 M | <0.01% | <0.01% | +184% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 911 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 135 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 79 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 47 | $0 M | <0.01% | <0.01% | +6.8% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 19 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Kalaris Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | BioCapital L.p. Samsara10% owner | Buyindirect | +244,300 | $4.830 | $1.2 M | 2.22 M | Form 4 |
| filed | BioCapital L.p. Samsara10% owner | Otherindirect | -66,906 | — | — | 10.66 M | Form 4 |
| filed | BioCapital L.p. Samsara10% owner | Otherindirect | +14,937 | — | — | 14,937 | Form 4 |
| filed | BioCapital L.p. Samsara10% owner | Otherindirect | +4,471 | — | — | 19,408 | Form 4 |
| filed | Brett R. HagenChief Accounting Officer | Sell | -1,915 | $6.720 | $13 K | 0 | Form 4 |
| filed | Srinivas AkkarajuDirector, 10% owner | Grant or awardindirect | +1.50 M | $10.00 | $15.0 M | 1.50 M | Form 4 |
| filed | Samsara Opportunity Fund, L.P.10% owner | Buyindirect | +479,847 | $10.42 | $5.0 M | 1.98 M | Form 4 |
| filed | Brett R. HagenChief Accounting Officer | Sell | -907 | $8.970 | $8 K | 1,925 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Kalaris Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-09-03 15:28 UTC, code LUDP, resumed 15:38 UTC
- 2025-09-03 15:23 UTC, code LUDP, resumed 15:28 UTC
- 2025-09-03 15:10 UTC, code LUDP, resumed 15:20 UTC
- 2025-09-03 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2025-04-10 15:42 UTC, code LUDP, resumed 15:47 UTC
Fails to deliver
- : 58 shares at $1.87
- : 364 shares at $2.90
- : 13,446 shares at $3.25
- : 17,820 shares at $3.20
- : 1,194 shares at $3.16
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Kalaris Therapeutics, Inc. scorecard#
Passes 3 of the 11 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-86.6%Free cash flow is -86.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.85 vs -51.77Diluted EPS -2.85 in fiscal 2025 against -51.77 the year before (report's currency).
- ✓Net income higher than five years earlier-$43 M-$43 M in fiscal 2025 against -$70 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$43 MNet income -$43 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities12.2×Current ratio 12.24 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-32.0×Operating income -32.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Kalaris Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | 0.2—100% | |
| Research and development | 31−31.7%— | 45r12−66.2%— | 133+11.9%— | 119−1.5%— | 121+143%— | 50+206%— | 16—9847% | |
| General and administrative | 15+130%— | 6.7r43−86.1%— | 48−7.8%— | 52+6.6%— | 49+127%— | 22+104%— | 11—6435% | |
| Operating expenses | 46−10.8%— | 52r65−74.1%— | 200+16.8%— | 171+0.8%— | 170+138%— | 71+165%— | 27—16282% | |
| Operating income | −46—— | −52r−65—— | −200—— | −171—— | −170—— | −71—— | −27—−16182% | |
| Interest and finance income | — | 5.5−4.3%— | 5.7+206%— | 1.9+42.7%— | 1.3−1.1%— | 1.3−35.6%— | 2.1—1252% | |
| Interest expense and finance costs | 1.4−46.6%— | 2.7—— | — | — | — | — | — | |
| Other non-operating income (expense) | 2.7—— | −17r1.2−581%— | 3.6+932%— | 0.4—— | −2.5−1357%— | 0.2−75.5%— | 0.8—483% | |
| Income before tax | −43—— | −69r−59—— | −191—— | −169—— | −171—— | −70—— | −24—−14448% | |
| Income tax | 0—— | 0—— | −0.1—— | −0.3−126%— | 1.0—— | — | — | |
| Net income including minority interests | −43—— | −69r−59—— | −190—— | −169—— | −172—— | −70—— | −24—−14448% | |
| Net income attributable to shareholders | −43—— | −69r−59—— | −190—— | −169—— | −172—— | −70—— | −24—−14448% | |
| Earnings per share, basic | -2.85—— | -51.77r-11.73—— | -42.09r-1.83—— | -2.20—— | -2.74—— | -2.59—— | -18.54—— | |
| Earnings per share, diluted | -2.85—— | -51.77r-11.73—— | -42.09r-1.83—— | -2.20—— | -2.74—— | -2.59—— | -18.54—— | |
| Shares, weighted average (basic) | 15+1043%— | 1.3r5.0−70.5%— | 4.5r104−94.1%— | 77+22.1%— | 63—— | — | — | |
| Shares, weighted average (diluted) | 15+1043%— | 1.3r5.0−70.5%— | 4.5r104−94.1%— | 77+22.1%— | 63+133%— | 27+1992%— | 1.3—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 98+5883%80.5% | 1.6r118−98.2%26.6% | 90−15.1%47.2% | 106−47.4%38.3% | 202+64.4%70.4% | 123+101%33.1% | 61—43.8% | |
| Short-term investments | 20—16.4% | 0−100%0.0% | 94−26.5%49.2% | 128+175%46.1% | 46−80.1%16.2% | 234+260%63.0% | 65—46.6% | |
| Other current assets | 0.8−14.5%0.7% | 1.0r0.3−72.3%15.7% | 3.5−50.9%1.8% | 7.1+37.1%2.6% | 5.2+14.0%1.8% | 4.5+572%1.2% | 0.7—0.5% | |
| Current assets | 119+4459%97.6% | 2.6r119−98.6%42.3% | 188−22.8%98.3% | 243−4.1%87.7% | 253−29.9%88.4% | 361+184%97.4% | 127—91.3% | |
| Property, plant and equipment | — | — | — | 0.9−40.0%0.3% | 1.5+90.8%0.5% | 0.8+132%0.2% | 0.4—0.3% | |
| Right-of-use (leased) assets | 1.5—1.2% | 0−100%0.0% | 2.2−93.1%1.1% | 32+6.4%11.4% | 30+242%10.4% | 8.7−26.1%2.3% | 12—8.4% | |
| Total assets | 122+1876%100% | 6.2r119−96.8%100% | 191−31.1%100% | 277−3.3%100% | 287−22.7%100% | 371+166%100% | 139—100% | |
| Accounts payable | 1.3−17.9%1.1% | 1.6r0.2−76.9%25.3% | 6.8+125%3.5% | 3.0−64.1%1.1% | 8.4+768%2.9% | 1.0+52.9%0.3% | 0.6—0.5% | |
| Current liabilities | 9.7−60.7%8.0% | 25r5.2−12.9%401% | 28+16.6%14.9% | 24−35.7%8.8% | 38+208%13.2% | 12+35.0%3.3% | 9.1—6.5% | |
| Lease liabilities (non-current) | 1.1—0.9% | 0−100%0.0% | 17−41.0%8.7% | 28+20.2%10.2% | 23+330%8.2% | 5.5−37.1%1.5% | 8.7—6.2% | |
| Total liabilities | 43−24.4%35.3% | 57r5.2+26.1%921% | 45−14.4%23.6% | 53−14.3%19.0% | 61+245%21.4% | 18−0.2%4.8% | 18—12.8% | |
| Retained earnings | −160—−131% | −117r−715—−1892% | −656—−344% | −466—−168% | −297—−104% | −125—−33.7% | −55—−39.7% | |
| Shareholders' equity | 79—64.7% | −97r113—−1568% | −45r146−120%−23.6% | 225−0.3%81.0% | 225−36.2%78.6% | 353—95.2% | −52—−36.9% | |
| Total liabilities and equity | 122+1876%100% | 6.2r119−96.8%100% | 191−31.1%100% | 277−3.3%100% | 287−22.7%100% | 371+166%100% | 139—100% | |
| Shares outstanding | 23+1588%— | 1.4r5.0−72.7%— | 5.0r114−94.7%— | 93+46.5%— | 64+2.6%— | 62+2849%— | 2.1—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | — | — | 0.4−45.0%— | 0.7+283%— | 0.2+159%— | 0.1+284%— | 0.0—11.5% | |
| Share-based compensation | 1.9+116%— | 0.9r26−97.8%— | 41−1.3%— | 41−6.0%— | 44+366%— | 9.4+226%— | 2.9—1752% | |
| Cash from operating activities | −38—— | −21r−68—— | −124—— | −142—— | −106—— | −61—— | −20—−12215% | |
| Capital expenditure | −0.2—— | — | — | — | −0.0—— | −0.2—— | −0.3—−205% | |
| Cash from investing activities | −20−121%— | 95+150%— | 38—— | −80−143%— | 186—— | −169—— | −65—−39178% | |
| Shares issued | 42—— | — | — | 126—— | — | — | — | |
| Cash from financing activities | 155+710%— | 19r0.0−72.8%— | 70−44.5%— | 127+54625%— | 0.2−99.9%— | 292+141%— | 121—73287% | |
| Exchange-rate effect on cash | — | — | — | — | −0.0—— | −0.1—— | — | |
| Change in cash | 97—— | −1.5r27—— | −16—— | −96−220%— | 80+29.7%— | 62+70.5%— | 36—21893% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 32+16.9%— | 8.3−8.6%— | 9.0+6.8%— | 7.6+25.6%— | 7.2*+85.9%— | 9.1−74.7%— | 8.4+163%— | 6.0+207%— | 3.9*−88.5%— | 36—— | 3.2r0.1—— | 2.0r12—— | 33*—— | |
| General and administrative | 15−2.0%— | 3.5−4.1%— | 3.4−11.7%— | 4.3−1.5%— | 3.6*+11.0%— | 3.6+97.6%— | 3.8+291%— | 4.3+618%— | 3.3r19*−68.6%— | 1.8r5.9—— | 1.0r7.2—— | 0.6r11—— | 10*—— | |
| Operating expenses | 47+10.2%— | 12−7.3%— | 12+1.1%— | 12+14.3%— | 11*+51.4%— | 13−66.3%— | 12+193%— | 10+304%— | 7.1r21*−88.6%— | 38—— | 4.2r7.8—— | 2.6r32—— | 62*—— | |
| Operating income | −47—— | −12—— | −12—— | −12—— | −11*—— | −13—— | −12—— | −10—— | −7.1r−20*—— | −38r−5.7—— | −4.2r−7.8—— | −2.6r−32—— | −62*—— | |
| Interest and finance income | — | — | — | — | — | — | — | — | 1.4*+1.0%— | 1.5—— | 1.4—— | 1.2—— | 1.4*—— | |
| Interest expense and finance costs | 0−100%— | 0—— | 0—— | 0−100%— | 0*−100%— | 0−100%— | 0−100%— | 1.4+1750%— | 1.3*—— | 0.8—— | 0.5—— | 0.1—— | — | |
| Other non-operating income (expense) | 3.4—— | 0.8−7.3%— | 0.9−3.9%— | 1.0+518%— | 0.8*—— | 0.8—— | 0.9—— | 0.2—— | −15*−1329%— | −0.2r0.1—— | −1.5r0.3—— | −0.8r0.8—— | 1.2*—— | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | −60*—— | |
| Income tax | — | — | — | — | — | — | — | — | 0*—— | 0—— | 0—— | 0—— | −0.1*—— | |
| Net income including minority interests | −43—— | −11*—— | −12*—— | −11—— | −10.0*—— | −12*—— | −11*—— | −10—— | −22r−18*—— | −38r−4.1*—— | −5.7r−6.1*—— | −3.4r−30—— | −60*—— | |
| Net income attributable to shareholders | −43—— | −11—— | −12—— | −11—— | −10.0*—— | −12—— | −11—— | −10—— | −22r−18*—— | −38r−4.1—— | −5.7r−6.1—— | −3.4r−30—— | −60*—— | |
| Earnings per share, basic | — | -0.46—— | -0.48—— | -0.46—— | — | -0.64—— | -0.61—— | -2.52—— | — | -28.16r-0.04—— | -4.26r-0.05—— | -2.60r-0.26—— | — | |
| Earnings per share, diluted | — | -0.46—— | -0.48—— | -0.46—— | — | -0.64—— | -0.61—— | -2.52—— | — | -28.16r-0.04—— | -4.26r-0.05—— | -2.60r-0.26—— | — | |
| Shares, weighted average (basic) | 24+27.3%— | 24+27.3%— | 24+27.2%— | 24+485%— | — | 19+1283%— | 19+1311%— | 4.1+209%— | — | 1.4r115—— | 1.3r115—— | 1.3r115—— | — | |
| Shares, weighted average (diluted) | 24+27.3%— | 24+27.3%— | 24+27.2%— | 24+485%— | — | 19+1283%— | 19+1311%— | 4.1+209%— | — | 1.4r115—— | 1.3r115—— | 1.3r115—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 47—53.2% | 47+11.8%53.2% | 43−51.2%43.4% | 34−65.9%31.4% | 98+5883%80.5% | 42+2116%52.2% | 88+1317%95.2% | 101+1832%97.9% | 1.6r118−98.2%26.6% | 1.9r117—1.6% | 6.2r105—4.8% | 5.2r86—3.6% | 90—47.2% | |
| Short-term investments | 35—39.9% | 35+2.5%39.9% | 50—50.6% | 63—57.2% | 20—16.4% | 35+593%42.6% | — | — | 0−100%0.0% | 5.0—4.1% | 25—19.0% | 54—37.8% | 94—49.2% | |
| Other current assets | 1.8—2.0% | 1.8+52.5%2.0% | 1.9−42.0%1.9% | 0.9−29.3%0.8% | 0.8−14.5%0.7% | 1.2+89.1%1.5% | 3.2+1302%3.5% | 1.2+57.8%1.2% | 1.0r0.3−72.3%15.7% | 0.6—0.5% | 0.2—0.2% | 0.8—0.5% | 3.5—1.8% | |
| Current assets | 85—95.7% | 85+8.9%95.7% | 96+4.7%96.4% | 98−3.6%89.7% | 119+4459%97.6% | 78−36.2%96.3% | 92−29.5%98.7% | 102−27.8%99.1% | 2.6r119−98.6%42.3% | 123—100% | 130—99.2% | 141—98.2% | 188—98.3% | |
| Right-of-use (leased) assets | 1.3—1.5% | 1.3−11.2%1.5% | 1.4—1.4% | 1.4—1.3% | 1.5—1.2% | 1.5—1.9% | — | — | 0−100%0.0% | — | 0.5—0.4% | 2.1—1.5% | 2.2—1.1% | |
| Total assets | 89—100% | 89+9.6%100% | 100+7.2%100% | 110+6.5%100% | 122+1876%100% | 81−33.8%100% | 93−29.1%100% | 103−28.5%100% | 6.2r119−96.8%100% | 123—100% | 131—100% | 144—100% | 191—100% | |
| Accounts payable | 2.8—3.1% | 2.8+457%3.1% | 1.1−69.5%1.1% | 0.9−61.9%0.8% | 1.3−17.9%1.1% | 0.5+869%0.6% | 3.7+3245%4.0% | 2.4+210%2.3% | 1.6r0.2−76.9%25.3% | 0.1—0.0% | 0.1—0.1% | 0.8—0.5% | 6.8—3.5% | |
| Current liabilities | 8.5—9.6% | 8.5+40.4%9.6% | 8.7+14.2%8.8% | 8.1+13.1%7.4% | 9.7−60.7%8.0% | 6.1+330%7.5% | 7.7+224%8.2% | 7.1−6.7%6.9% | 25r5.2−12.9%401% | 1.4—1.2% | 2.4—1.8% | 7.7—5.3% | 28—14.9% | |
| Lease liabilities (non-current) | 1.0—1.1% | 1.0−13.5%1.1% | 1.1—1.1% | 1.1—1.0% | 1.1—0.9% | 1.2—1.4% | — | — | 0−100%0.0% | — | 8.3—6.4% | 16—11.1% | 17—8.7% | |
| Total liabilities | 42—46.7% | 42+5.8%46.7% | 42+5.4%42.1% | 41+5.2%37.6% | 43−24.4%35.3% | 39+2684%48.4% | 40+271%42.8% | 39+65.5%38.0% | 57r5.2+26.1%921% | 1.4—1.2% | 11—8.2% | 24—16.4% | 45—23.6% | |
| Retained earnings | −193—−217% | −193—−217% | −182—−183% | −171—−156% | −160—−131% | −150—−185% | −138—−149% | −127—−123% | −117r−715—−1892% | −697—−569% | −693—−529% | −686—−476% | −656—−344% | |
| Shareholders' equity | 47—53.3% | 47+13.2%53.3% | 58+8.6%57.9% | 69+7.3%62.4% | 79—64.7% | 42—51.6% | 53—57.2% | 64—62.0% | −97r113—−1568% | −89r121—−72.9% | −52r120—−39.3% | −48r120—−33.0% | −45r146—−23.6% | |
| Total liabilities and equity | 89—100% | 89+9.6%100% | 100+7.2%100% | 110+6.5%100% | 122+1876%100% | 81−33.8%100% | 93−29.1%100% | 103−28.5%100% | 6.2r119−96.8%100% | 123—100% | 131—100% | 144—100% | 191—100% | |
| Shares outstanding | 24—— | 24+27.3%— | 24+27.3%— | 23+22.9%— | 23+1588%— | 19−83.8%— | 19−83.8%— | 19−83.7%— | 1.4r5.0−72.7%— | 115—— | 115—— | 115—— | 5.0r114—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | — | 0.1*—— | |
| Share-based compensation | 2.3+22.6%— | 0.8+17.9%— | 0.6+9.0%— | 0.6+55.1%— | 0.3*+18.9%— | 0.6+144%— | 0.6+83.5%— | 0.4+1106%— | 0.3r10*−97.2%— | 0.3r4.9—— | 0.3r5.9—— | 0.0r5.0—— | 10.0*—— | |
| Cash from operating activities | −40—— | −11*—— | −11*—— | −12—— | −7.1*—— | −11*—— | −13*—— | −7.4—— | −7.9r−3.6*—— | −4.3r−8.4*—— | −4.0r−11*—— | −4.5r−44—— | −31*—— | |
| Capital expenditure | — | — | — | — | −0.0*—— | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −0.4—— | 15*—— | 20*—— | −50—— | 15*+200%— | — | — | — | 5.0*−80.2%— | 20*—— | 30*—— | 40—— | 25*—— | |
| Cash from financing activities | 46−60.3%— | −0.1*—— | −0.4*—— | −1.7−102%— | 48*+530%— | 0*−100%— | 0*−100%— | 107+1530%— | 7.6r0*+68782%— | 0.0r0*—— | 5.0r−6.6*—— | 6.6—— | 0.0*—— | |
| Change in cash | 5.0−87.8%— | 4.2*—— | 8.7*—— | −64−164%— | 56*—— | −46*—— | −13*−1339%— | 100+4751%— | −0.3r1.4*—— | −4.3r12*—— | 1.0r19*—— | 2.1r−4.4—— | −5.5*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Kalaris Therapeutics, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
| 🇮🇹 Italy | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Kalaris Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Andrew Oxtoby, Vikas Sinha | $2.6 M | $4.5 M | $1.4 M | $54 |
| 2024Diana Brainard, Vikas Sinha | $3.0 M | $2.8 M | $721 K | $62 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Kalaris Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Change in control 1 · Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Change in controlAcquisition or sale completedDirectors and officersBylaws or fiscal year changedResults announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 95% of workforce | Restructuring planSEC 8-K | “(“AlloVir”) approved a reduction its workforce by approximately 95% of AlloVir’s current employee base in order to reduce costs and preserve capital in light of AlloVir’s announcem…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Kalaris Therapeutics, Inc. compares in Biotechnology
- Market cap$45 M · higher than 24% of 726
- Price / book0.6× · lower than 90% of 534
- FCF yield-86.6% · higher than 12% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kalaris Therapeutics, Inc.🇺🇸 | $45 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kalaris Therapeutics, Inc.? Verify and update this profile — free
Show Kalaris Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.